Evotec SE stock (DE0005664809): shares stabilize while investors watch technical picture

Evotec SE shares showed a calmer session on the German Xetra market toward the end of May, with the stock quoted around EUR 5.00 after a period of pronounced weakness over the past year, keeping the Hamburg-based biotech group on the radar of domestic investors on the Frankfurt exchange.

According to data from Xetra, Evotec SE trades under the ticker EVT in Germany, where the stock is part of the TecDAX segment and remains a notable name in the country’s listed biotechnology space.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

Evotec SE: core business model

Evotec SE focuses on partnering with pharmaceutical and biotech companies to design, develop and advance drug candidates across multiple therapeutic areas, generating revenue from discovery alliances, co-development projects and related service contracts.

Chart technicals and 52-week range

From a technical point of view, Evotec SE’s share price on Xetra has moved within a clearly defined corridor over the past 12 months, with market data indicating that the stock has fallen significantly compared with levels seen one year earlier while recently stabilizing in the low single-digit euro range.

The 52-week span on the German market shows that Evotec SE has traded between a lower band in the low single digits and a markedly higher peak in the same period, underscoring the stock’s volatility profile and the sensitivity of its price to news flow and sector sentiment in the German TecDAX environment.

Conclusion

Evotec SE’s share price on Xetra has entered a quieter phase at the end of May, with the stock holding near recent levels after a challenging year for investors.

With the technical picture showing a broad 52-week range and continuing volatility, the market will likely keep tracking both company-specific announcements and sector news when reassessing the German biotech group’s valuation on the Frankfurt-linked trading venues.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.